Sponsor or institution

Clinical trials and research at Chong Kun Dang Pharmaceutical

• 7Clinical trials
• 5Countries

Newest trials

All recruiting trials (7)

• First-in-human test of CKD-703 for advanced solid tumors and non-small cell lung cancer

  This trial will test CKD-703, a targeted antibody–drug conjugate, in adults with advanced c‑Met–expressing solid tumors and in MET‑amplified or c‑Met–overexpressing non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1/2 Chong Kun Dang Pharmaceutical · Ohio City, Ohio · NCT07439094

• Comparison of CKD-706 and US/EU Dupixent pharmacology in healthy adults.

  We will test whether CKD-706 behaves like the US and EU versions of Dupixent in healthy adults after a single 300 mg dose by measuring blood drug levels, immune response, and safety over 85 days.

  Recruiting Phase 1 Chong Kun Dang Pharmaceutical · Berlin, State of Berlin and 1 other locations · NCT07358156

• PK and safety comparison of CKD-704 (risankizumab biosimilar) with EU and US Skyrizi in healthy adults

  This Phase 1 trial will test whether CKD-704, a risankizumab biosimilar, behaves like the EU and US versions of Skyrizi in healthy adults.

  Recruiting Phase 1 Chong Kun Dang Pharmaceutical · Warsaw, Warszawa · NCT07258745

• CKD-512 alone and with pembrolizumab for advanced or metastatic solid tumors

  This study will try CKD-512 by itself and together with pembrolizumab in people with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Chong Kun Dang Pharmaceutical · Seoul · NCT07215637

• CKD-843 for male pattern baldness: a new treatment in Phase 3

  We’re testing CKD-843 in men aged 18–50 with androgenetic alopecia to see if it helps hair loss over 12 months.

  Recruiting Phase 3 Chong Kun Dang Pharmaceutical · Seoul · NCT06916793

• Evaluating the safety and effectiveness of triple therapy for Type 2 diabetes in Korean patients

  This study is testing if a new combination of diabetes medications can help Korean patients with Type 2 diabetes who aren't getting good results from their current treatments.

  Recruiting Chong Kun Dang Pharmaceutical · Seongnam-si, Gyeonggi-do · NCT06838286

• CKD-202A (sacubitril/valsartan) for adults with high blood pressure

  This trial will test whether CKD-202A (sacubitril/valsartan) controls blood pressure safely in adults with essential hypertension compared with valsartan.

  Recruiting Phase 3 Chong Kun Dang Pharmaceutical · Wŏnju · NCT06643819

Quick answers

How many clinical trials run by Chong Kun Dang Pharmaceutical are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in South Korea (4 trials), Germany (1 trial), United Kingdom (1 trial), Poland (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →